

# Executive Board agenda item on “Antimicrobial Resistance: accelerating national and global responses”

## Briefing for Member States

**Dr Hanan Balkhy**

Assistant Director-General, AMR Division  
Regional Director Elect for the Eastern Mediterranean


**Dr Kitty van Weezenbeek**

Director, AMR Surveillance, Prevention and Control



## Background

- Pursuant to document A76/37 (2023) and resolution WHA72.5 (2019), and in preparation for the 2024 high-level meeting of the United Nations General Assembly on antimicrobial resistance;
- The Director-General will present a report on **WHO strategic and operational priorities to address drug-resistant bacterial infections, 2025 – 2035**.
- The Board will be invited to note the report and provide guidance on next steps.



# Rationale (1): UNGA high-level meeting in September 2024, and urgent need for accelerated action on AMR

**1.27**  
million deaths  
directly  
attributable to  
**bacterial AMR**  
per year<sup>1</sup>

**US\$ 1**  
trillion additional  
healthcare  
Costs by 2050<sup>2</sup>

**US\$ 1 - 3.4**  
trillion  
projected annual  
GDP losses  
by 2030<sup>2</sup>

- **Multisectoral Global Action Plan on AMR (GAP-AMR)** was adopted by the World Health Assembly in 2015 – endorsed by other sectors
- Other sectors (Food and Agriculture Organization, World Organisation for Animal Health, United Nations Environment Program) have all developed a **sector-specific strategy** or high-level report on AMR
- **Human health sector does not have a specific strategy to address drug-resistant bacterial infections (bacterial AMR) in a comprehensive manner** – challenge to all modern medicine
- 90% of countries have a **multi-sectoral AMR national action plan (NAP)**; only 25% are implementing effectively, 10% allocated funding through their national budgets to do so; implementation is very fragmented and ad-hoc
- Urgent need to address key drivers of AMR: **mis- and over-use of antimicrobials**; weak antibiotics (R&D) pipeline + access crisis

1. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. The Lancet 2022 <https://www.sciencedirect.com/science/article/pii/S0140673621027240?via%3DIihub>; 2. <https://www.worldbank.org/en/topic/health/publication/drug-resistant-infections-a-threat-to-our-economic-future>

## Rationale (2): AMR at the 76th World Health Assembly

*Director-General's progress report in May 2023 highlighted 3 key actions*

- **Support development of UNGA 2024 commitments:** targets, financing, access, R&D
- **Accelerate AMR national action plan implementation & monitoring:** urgent funding & technical support needs
- **Develop a strategic & operational framework for drug-resistant bacterial infections in humans**
  - Focus: prevention, equitable access, innovation, strategic information, people-centred, aligned with PHC/UHC and HEPR plans; solidarity to address global threat



# EB paper: Report on proposed *Strategic and operational priorities to address drug-resistant bacterial infections, 2025-2035*

**Vision:** Control and reverse the urgent public health and socioeconomic crisis due to drug-resistant infections in humans

**Aim:** Slow the emergence and spread of drug-resistant bacterial infections and preserve effective antibiotics for future generations



*Strategic priority 1:*

**PREVENTION OF INFECTIONS**



*Strategic priority 2:*

**UNIVERSAL ACCESS**  
to affordable, quality diagnosis and appropriate treatment of infections



*Strategic priority 3:*

**STRATEGIC INFORMATION AND INNOVATION**

*Operational priorities (1):*

**THE PEOPLE-CENTRED APPROACH AND CORE PACKAGE OF COUNTRY-LEVEL INTERVENTIONS**

- Core package of 13 interventions for integration in PHC and HEPR



*Operational priorities (2):*

**ENABLING ACTIONS TO SUPPORT MEMBER STATES**

- Technical assistance + coordination of global or regional action and partnerships

## Action for the Executive Board


*The Executive Board is invited to note the report [and] to provide guidance on how the Secretariat can best support Member States in:*

- **Incorporating the strategic and operational priorities** to address drug-resistant bacterial infections in **AMR national action plans**;
- **Strengthening financing and governance** of AMR national action plans to accelerate and sustain implementation;
- Ensuring the strategic and operational priorities to address drug-resistant infections in the human health sector are reflected in discussions and outcomes of the **UNGA high-level meeting on AMR in September 2024**.



## Next steps

- **Member States consultation (online)**
  - Strategic and operational priorities
    - *The People-Centred Approach and core AMR interventions already underwent a global consultation with MS and other stakeholders + expert advisory input including STAG-AMR*
  - Potential indicators



Thank you;  
Questions and answers

